Announcements Trials
Browse Landscape

Phase

Phase 1 11Phase 3 5Phase 2 5Phase 1/2 3Phase NA 2Phase 4 2Phase EARLY_PHASE1 1

Status

Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2NET 1Endocrine 1Dermatologic 1

Conditions

Prostatic Neoplasms 2Urogenital Neoplasms 1Prostatic Diseases 1Neuroendocrine Tumors 1Carcinoma, Merkel Cell 1Carcinoma 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Lutetium-177 × Clear all
NCT05413850 2026-05-14

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Blue Earth Therapeutics Ltd

Phase 1/2 Recruiting
82 enrolled
Genitourinary

Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT04261855 2026-03-27

GoTHAM

Melanoma and Skin Cancer Trials Limited

Phase 1/2 Active not recruiting
19 enrolled
DermatologicEndocrineNET

Carcinoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT06881823 2025-12-29

NeoPSMA

Novartis

Phase 1/2 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡